{"protocolSection": {"identificationModule": {"nctId": "NCT01256411", "orgStudyIdInfo": {"id": "CLCZ696A2219E1"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertension", "officialTitle": "An Open-label, Long-term Extension Study to Evaluate the Safety, Tolerability and Efficacy of 12 Months of LCZ696 Treatment in Patients With Essential Hypertension"}, "statusModule": {"statusVerifiedDate": "2015-09", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-11"}, "primaryCompletionDateStruct": {"date": "2012-04", "type": "ACTUAL"}, "completionDateStruct": {"date": "2012-04", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-12-07", "studyFirstSubmitQcDate": "2010-12-07", "studyFirstPostDateStruct": {"date": "2010-12-08", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-07-21", "resultsFirstSubmitQcDate": "2015-09-22", "resultsFirstPostDateStruct": {"date": "2015-10-21", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-09-22", "lastUpdatePostDateStruct": {"date": "2015-10-21", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The purpose of this study is to assess the long-term safety, tolerability and efficacy of LCZ696."}, "conditionsModule": {"conditions": ["Essential Hypertension"], "keywords": ["hypertension", "blood pressure", "LCZ696", "dual-acting", "neprilysin", "nep inhibitor", "vasopeptidase", "angiotensin receptor", "angiotensin receptor neprilysin inhibitor (ARNi)"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 341, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "LCZ696", "type": "EXPERIMENTAL", "interventionNames": ["Drug: LCZ696", "Drug: Amlodipine", "Drug: Hydrochlorothiazide (HCTZ)"]}], "interventions": [{"type": "DRUG", "name": "LCZ696", "description": "Participants received LCZ696 200 mg as the starting dose with optional down titration to 100 mg for tolerance and optional up titration to 400 mg for adequate blood pressure control.", "armGroupLabels": ["LCZ696"]}, {"type": "DRUG", "name": "Amlodipine", "description": "Optional add-on of amlodipine (5-10 mg) was allowed (as applicable per local country regulations) for adequate blood pressure control.", "armGroupLabels": ["LCZ696"]}, {"type": "DRUG", "name": "Hydrochlorothiazide (HCTZ)", "description": "Optional add-on of hydrochlorothiazide (HCTZ) (12.5-25 mg) was allowed (as applicable per local country regulations) for adequate blood pressure control.", "armGroupLabels": ["LCZ696"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Participants With Adverse Events, Serious Adverse Events, and Deaths (Analysis by Actual Treatment)", "description": "Participants were monitored throughout the study for adverse events, serious adverse events and deaths.", "timeFrame": "Baseline to 12 months"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP) (Analysis by Maximum Treatment)", "description": "Sitting BP measurements were performed at every study visit. A negative change from baseline indicates improvement.", "timeFrame": "Baseline, 12 months"}, {"measure": "Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP) (Analysis by Mono or Combination Therapy)", "description": "Sitting BP measurements were performed at every study visit. A negative change from baseline indicates improvement.", "timeFrame": "Baseline, 12 months"}, {"measure": "Number of Participants With Blood Pressure Control Rate of <140/90 mmHg (Analysis by Maximum Treatment)", "description": "Blood pressure (BP) control is defined as BP \\<140/90 mmHg.", "timeFrame": "Baseline to 12 months"}, {"measure": "Number of Participants With Blood Pressure Control Rate of <140/90 mmHg (Analysis by Mono or Combination Therapy)", "description": "Blood pressure (BP) control is defined as BP \\<140/90 mmHg.", "timeFrame": "Baseline to 12 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients who have successfully completed protocol No. CLCZ696A2219 and who, as judged by the study investigator, are able to continue in the current study.\n* Ability to communicate and comply with all study requirements and demonstrate good medication compliance during CLCZ696A2219.\n\nExclusion Criteria:\n\n* Patients who did not complete CLCZ696A2219.\n* Presence of significant protocol violation in CLCZ696A2219.\n* Patients who are deemed to be unable to comply with the protocol by the investigator.\n* Other protocol-defined inclusion/exclusion criteria may apply", "healthyVolunteers": false, "sex": "ALL", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novartis Investigative Site", "city": "Chongqing", "state": "Chongqing", "zip": "400042", "country": "China", "geoPoint": {"lat": 29.56278, "lon": 106.55278}}, {"facility": "Novartis Investigative Site", "city": "Shijiazhuang", "state": "Hebei", "zip": "050000", "country": "China", "geoPoint": {"lat": 38.04139, "lon": 114.47861}}, {"facility": "Novartis Investigative Site", "city": "Hangzhou", "state": "Zhejiang", "zip": "310006", "country": "China", "geoPoint": {"lat": 30.29365, "lon": 120.16142}}, {"facility": "Novartis Investigative Site", "city": "Beijing", "zip": "100044", "country": "China", "geoPoint": {"lat": 39.9075, "lon": 116.39723}}, {"facility": "Novartis Investigative Site", "city": "Beijing", "zip": "100730", "country": "China", "geoPoint": {"lat": 39.9075, "lon": 116.39723}}, {"facility": "Novartis Investigative Site", "city": "Tianjin", "zip": "300142", "country": "China", "geoPoint": {"lat": 39.14222, "lon": 117.17667}}, {"facility": "Novartis Investigative Site", "city": "Yokohama-city", "state": "Kanagawa", "zip": "231-0023", "country": "Japan", "geoPoint": {"lat": 35.43333, "lon": 139.65}}, {"facility": "Novartis Investigative Site", "city": "Shimotsuke-city", "state": "Tochigi", "zip": "329-0498", "country": "Japan", "geoPoint": {"lat": 36.41323, "lon": 139.86622}}, {"facility": "Novartis Investigative Site", "city": "Bunkyo-ku", "state": "Tokyo", "zip": "113-0031", "country": "Japan", "geoPoint": {"lat": 35.37517, "lon": 139.92991}}, {"facility": "Novartis Investigative Site", "city": "Chiyoda-ku", "state": "Tokyo", "zip": "100-0005", "country": "Japan"}, {"facility": "Novartis Investigative Site", "city": "Kiyose-city", "state": "Tokyo", "zip": "204-0021", "country": "Japan"}, {"facility": "Novartis Investigative Site", "city": "Kunitachi", "state": "Tokyo", "zip": "186-0001", "country": "Japan", "geoPoint": {"lat": 35.6833, "lon": 139.43848}}, {"facility": "Novartis Investigative Site", "city": "Minato-ku", "state": "Tokyo", "zip": "105-7390", "country": "Japan", "geoPoint": {"lat": 34.2152, "lon": 135.1501}}, {"facility": "Novartis Investigative Site", "city": "Minato-ku", "state": "Tokyo", "zip": "108-0075", "country": "Japan", "geoPoint": {"lat": 34.2152, "lon": 135.1501}}, {"facility": "Novartis Investigative Site", "city": "Ota-ku", "state": "Tokyo", "zip": "143-0023", "country": "Japan", "geoPoint": {"lat": 36.3, "lon": 139.36667}}, {"facility": "Novartis Investigative Site", "city": "Shinagawa-ku", "state": "Tokyo", "zip": "141-0032", "country": "Japan", "geoPoint": {"lat": 33.63627, "lon": 133.00572}}, {"facility": "Novartis Investigative Site", "city": "Shinagawa-ku", "state": "Tokyo", "zip": "142-0053", "country": "Japan", "geoPoint": {"lat": 33.63627, "lon": 133.00572}}, {"facility": "Novartis Investigative Site", "city": "Shinagawa-ku", "state": "Tokyo", "zip": "142-0063", "country": "Japan", "geoPoint": {"lat": 33.63627, "lon": 133.00572}}, {"facility": "Novartis Investigative Site", "city": "Toshima-ku", "state": "Tokyo", "zip": "171-0021", "country": "Japan"}, {"facility": "Novartis Investigative Site", "city": "Bucheon", "state": "Gyeonggi-do", "zip": "424-717", "country": "Korea, Republic of", "geoPoint": {"lat": 37.49889, "lon": 126.78306}}, {"facility": "Novartis Investigative Site", "city": "Seoul", "state": "Korea", "zip": "137-701", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Novartis Investigative Site", "city": "Koyang", "state": "Kyunggi", "zip": "410-719", "country": "Korea, Republic of"}, {"facility": "Novartis Investigative Site", "city": "Daegu", "zip": "705-703", "country": "Korea, Republic of", "geoPoint": {"lat": 35.87028, "lon": 128.59111}}, {"facility": "Novartis Investigative Site", "city": "Seoul", "zip": "150-950", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Novartis Investigative Site", "city": "Seoul", "zip": "152-703", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Novartis Investigative Site", "city": "Changhua", "zip": "500", "country": "Taiwan", "geoPoint": {"lat": 24.07327, "lon": 120.56276}}, {"facility": "Novartis Investigative Site", "city": "Taichung", "zip": "40447", "country": "Taiwan", "geoPoint": {"lat": 24.1469, "lon": 120.6839}}, {"facility": "Novartis Investigative Site", "city": "Taipei", "zip": "10002", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}, {"facility": "Novartis Investigative Site", "city": "Taipei", "zip": "10449", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}, {"facility": "Novartis Investigative Site", "city": "Taipei", "zip": "114", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}, {"facility": "Novartis Investigative Site", "city": "Bangkok", "zip": "10400", "country": "Thailand", "geoPoint": {"lat": 13.75398, "lon": 100.50144}}, {"facility": "Novartis Investigative Site", "city": "Bangkok", "zip": "10700", "country": "Thailand", "geoPoint": {"lat": 13.75398, "lon": 100.50144}}, {"facility": "Novartis Investigative Site", "city": "Chiang Mai", "zip": "50200", "country": "Thailand", "geoPoint": {"lat": 18.79038, "lon": 98.98468}}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "Analyses on this open label extension study were performed according to treatment groups defined by the maximum and highest dose treatments received: 1) LCZ696 200 mg, 2) LCZ696 400 mg, 3) LCZ696 400 mg/Amlodipine, 4) LCZ696 400 mg/Amlodipine/HCTZ, 5) LCZ696 Mono (LCZ696 only), and 6) LCZ696 Combination LCZ696 with Amlodipine and/or HCTZ).", "groups": [{"id": "FG000", "title": "LCZ696 200 mg", "description": "Participants received LCZ696 200 mg by mouth once daily (qd)."}, {"id": "FG001", "title": "LCZ696 400 mg", "description": "Participants received LCZ696 400 mg by mouth qd."}, {"id": "FG002", "title": "LCZ606 400 mg/Amlodipine", "description": "Participants received LCZ696 400 mg by mouth qd and amlodipine 5mg up to 10 mg by mouth as needed (prn)."}, {"id": "FG003", "title": "LCZ696 400 mg/Amlodipine/HCTZ", "description": "Participants received LCZ696 400 mg by mouth qd, amlodipine 5 mg up to 10 mg by mouth prn and HCTZ 6.25 mg and up to 25 mg by mouth prn."}, {"id": "FG004", "title": "LCZ696 Monotherapy", "description": "Participants received LCZ696 only."}, {"id": "FG005", "title": "LCZ696 Combination Therapy", "description": "Participants received LCZ696 with amlodipine and/or HCTZ."}], "periods": [{"title": "Extension by Maximum Treatment", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "139"}, {"groupId": "FG001", "numSubjects": "89"}, {"groupId": "FG002", "numSubjects": "109"}, {"groupId": "FG003", "numSubjects": "4"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Down Titrated to 100 mg", "achievements": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "132"}, {"groupId": "FG001", "numSubjects": "79"}, {"groupId": "FG002", "numSubjects": "105"}, {"groupId": "FG003", "numSubjects": "4"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "10"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Protocol deviation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "Extension by Mono or Combination Therapy", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "228"}, {"groupId": "FG005", "numSubjects": "113"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "211"}, {"groupId": "FG005", "numSubjects": "109"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "17"}, {"groupId": "FG005", "numSubjects": "4"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "6"}, {"groupId": "FG005", "numSubjects": "1"}]}, {"type": "Protocol deviation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "3"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "7"}, {"groupId": "FG005", "numSubjects": "1"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "LCZ696 200 mg", "description": "Participants received LCZ696 200 mg by mouth once daily (qd)."}, {"id": "BG001", "title": "LCZ696 400 mg", "description": "Participants received LCZ696 400 mg by mouth qd."}, {"id": "BG002", "title": "LCZ606 400 mg/Amlodipine", "description": "Participants received LCZ696 400 mg by mouth qd and amlodipine 5mg up to 10 mg by mouth as needed (prn)."}, {"id": "BG003", "title": "LCZ696 400 mg/Amlodipine/HCTZ", "description": "Participants received LCZ696 400 mg by mouth qd, amlodipine 5 mg up to 10 mg by mouth prn and HCTZ 6.25 mg and up to 25 mg by mouth prn."}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "139"}, {"groupId": "BG001", "value": "89"}, {"groupId": "BG002", "value": "109"}, {"groupId": "BG003", "value": "4"}, {"groupId": "BG004", "value": "341"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "52.2", "spread": "9.69"}, {"groupId": "BG001", "value": "50.3", "spread": "10.14"}, {"groupId": "BG002", "value": "52.5", "spread": "9.53"}, {"groupId": "BG003", "value": "46.3", "spread": "2.06"}, {"groupId": "BG004", "value": "51.8", "spread": "9.73"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "55"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "26"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "99"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "84"}, {"groupId": "BG001", "value": "71"}, {"groupId": "BG002", "value": "83"}, {"groupId": "BG003", "value": "4"}, {"groupId": "BG004", "value": "242"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Participants With Adverse Events, Serious Adverse Events, and Deaths (Analysis by Actual Treatment)", "description": "Participants were monitored throughout the study for adverse events, serious adverse events and deaths.", "populationDescription": "Actual extension treatment received: The participants are included in each treatment group for which they received treatment. For example, if a participant started on LCZ696 200 mg but was then down-titrated to LCZ696 100 mg, the participant was counted once in the LCZ696 100 mg group and once in the LCZ696 200 mg group.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Baseline to 12 months", "groups": [{"id": "OG000", "title": "LCZ696 200 mg", "description": "Participants received LCZ696 200 mg by mouth once daily (qd)."}, {"id": "OG001", "title": "LCZ696 400 mg", "description": "Participants received LCZ696 400 mg by mouth qd."}, {"id": "OG002", "title": "LCZ606 400 mg/Amlodipine", "description": "Participants received LCZ696 400 mg by mouth qd and amlodipine 5mg up to 10 mg by mouth as needed (prn)."}, {"id": "OG003", "title": "LCZ696 400 mg/Amlodipine/HCTZ", "description": "Participants received LCZ696 400 mg by mouth qd, amlodipine 5 mg up to 10 mg by mouth prn and HCTZ 6.25 mg and up to 25 mg by mouth prn."}, {"id": "OG004", "title": "LCZ696 100 mg", "description": "Participants were down-titrated to 100 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "340"}, {"groupId": "OG001", "value": "201"}, {"groupId": "OG002", "value": "112"}, {"groupId": "OG003", "value": "4"}, {"groupId": "OG004", "value": "12"}]}], "classes": [{"title": "Adverse events (serious and non-serious)", "categories": [{"measurements": [{"groupId": "OG000", "value": "147"}, {"groupId": "OG001", "value": "78"}, {"groupId": "OG002", "value": "53"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "6"}]}]}, {"title": "Seroius adverse events", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "1"}]}]}, {"title": "Deaths", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP) (Analysis by Maximum Treatment)", "description": "Sitting BP measurements were performed at every study visit. A negative change from baseline indicates improvement.", "populationDescription": "Treated set: The treated set included all participants who received at least one dose of extension study medication. One participant in the LCZ696 400 mg/Amlodopine group discontinued after 1 day in the extension study without having any BP measurements taken during the extension. Therefore, this participant was excluded from the analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline, 12 months", "groups": [{"id": "OG000", "title": "LCZ696 200 mg", "description": "Participants received LCZ696 200 mg by mouth once daily (qd)."}, {"id": "OG001", "title": "LCZ696 400 mg", "description": "Participants received LCZ696 400 mg by mouth qd."}, {"id": "OG002", "title": "LCZ606 400 mg/Amlodipine", "description": "Participants received LCZ696 400 mg by mouth qd and amlodipine 5mg up to 10 mg by mouth as needed (prn)."}, {"id": "OG003", "title": "LCZ696 400 mg/Amlodipine/HCTZ", "description": "Participants received LCZ696 400 mg by mouth qd, amlodipine 5 mg up to 10 mg by mouth prn and HCTZ 6.25 mg and up to 25 mg by mouth prn."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "139"}, {"groupId": "OG001", "value": "89"}, {"groupId": "OG002", "value": "108"}, {"groupId": "OG003", "value": "4"}]}], "classes": [{"title": "msDBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "-16.6", "spread": "7.63"}, {"groupId": "OG001", "value": "-14.2", "spread": "7.05"}, {"groupId": "OG002", "value": "-17.4", "spread": "7.71"}, {"groupId": "OG003", "value": "-16.8", "spread": "3.84"}]}]}, {"title": "msSBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "-24.1", "spread": "12.16"}, {"groupId": "OG001", "value": "-21.3", "spread": "11.46"}, {"groupId": "OG002", "value": "-28.1", "spread": "13.43"}, {"groupId": "OG003", "value": "-29.0", "spread": "9.23"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP) (Analysis by Mono or Combination Therapy)", "description": "Sitting BP measurements were performed at every study visit. A negative change from baseline indicates improvement.", "populationDescription": "Treated set: The treated set included all participants who received at least one dose of extension study medication. One participant in the LCZ696 combination group discontinued after 1 day in the extension study without having any BP measurements taken during the extension. Therefore, this participant was excluded from the analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline, 12 months", "groups": [{"id": "OG000", "title": "LCZ696 Monotherapy", "description": "Participants received LCZ696 only."}, {"id": "OG001", "title": "LCZ696 Combination Therapy", "description": "Participants received LCZ696 with amlodipine and/or HCTZ."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "228"}, {"groupId": "OG001", "value": "112"}]}], "classes": [{"title": "msDBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "-15.7", "spread": "7.49"}, {"groupId": "OG001", "value": "-17.3", "spread": "7.60"}]}]}, {"title": "msSBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "-23.0", "spread": "11.95"}, {"groupId": "OG001", "value": "-28.2", "spread": "13.27"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Blood Pressure Control Rate of <140/90 mmHg (Analysis by Maximum Treatment)", "description": "Blood pressure (BP) control is defined as BP \\<140/90 mmHg.", "populationDescription": "Treated set: The treated set included all participants who received at least one dose of extension study medication. One participant in the LCZ696 400 mg/Amlodopine group discontinued after 1 day in the extension study without having any BP measurements taken during the extension. Therefore, this participant was excluded from the analysis.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Baseline to 12 months", "groups": [{"id": "OG000", "title": "LCZ696 200 mg", "description": "Participants received LCZ696 200 mg by mouth once daily (qd)."}, {"id": "OG001", "title": "LCZ696 400 mg", "description": "Participants received LCZ696 400 mg by mouth qd."}, {"id": "OG002", "title": "LCZ606 400 mg/Amlodipine", "description": "Participants received LCZ696 400 mg by mouth qd and amlodipine 5mg up to 10 mg by mouth as needed (prn)."}, {"id": "OG003", "title": "LCZ696 400 mg/Amlodipine/HCTZ", "description": "Participants received LCZ696 400 mg by mouth qd, amlodipine 5 mg up to 10 mg by mouth prn and HCTZ 6.25 mg and up to 25 mg by mouth prn."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "139"}, {"groupId": "OG001", "value": "89"}, {"groupId": "OG002", "value": "108"}, {"groupId": "OG003", "value": "4"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "114"}, {"groupId": "OG001", "value": "62"}, {"groupId": "OG002", "value": "77"}, {"groupId": "OG003", "value": "3"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Blood Pressure Control Rate of <140/90 mmHg (Analysis by Mono or Combination Therapy)", "description": "Blood pressure (BP) control is defined as BP \\<140/90 mmHg.", "populationDescription": "Treated set: The treated set included all participants who received at least one dose of extension study medication. One participant in the LCZ696 combination group discontinued after 1 day in the extension study without having any BP measurements taken during the extension. Therefore, this participant was excluded from the analysis.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Baseline to 12 months", "groups": [{"id": "OG000", "title": "LCZ696 Monotherapy", "description": "Participants received LCZ696 only."}, {"id": "OG001", "title": "LCZ696 Combination Therapy", "description": "Participants received LCZ696 with amlodipine and/or HCTZ."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "228"}, {"groupId": "OG001", "value": "112"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "176"}, {"groupId": "OG001", "value": "80"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "2", "eventGroups": [{"id": "EG000", "title": "LCZ696 100 mg", "description": "Participants were down-titrated to 100 mg.", "seriousNumAffected": 1, "seriousNumAtRisk": 12, "otherNumAffected": 6, "otherNumAtRisk": 12}, {"id": "EG001", "title": "LCZ696 200 mg", "description": "Participants received LCZ696 200 mg by mouth once daily (qd).", "seriousNumAffected": 10, "seriousNumAtRisk": 340, "otherNumAffected": 77, "otherNumAtRisk": 340}, {"id": "EG002", "title": "LCZ696 400 mg", "description": "Participants received LCZ696 400 mg by mouth qd.", "seriousNumAffected": 2, "seriousNumAtRisk": 201, "otherNumAffected": 39, "otherNumAtRisk": 201}, {"id": "EG003", "title": "LCZ696 400 mg/Aml", "description": "Participants received LCZ696 400 mg by mouth qd, amlodipine 5 mg up to 10 mg by mouth prn and HCTZ 6.25 mg and up to 25 mg by mouth prn.", "seriousNumAffected": 0, "seriousNumAtRisk": 112, "otherNumAffected": 32, "otherNumAtRisk": 112}, {"id": "EG004", "title": "LCZ696 400 mg/Aml/HCTZ", "description": "Participants received LCZ696 400 mg by mouth qd, amlodipine 5 mg up to 10 mg by mouth prn and HCTZ 6.25 mg and up to 25 mg by mouth prn.", "seriousNumAffected": 0, "seriousNumAtRisk": 4, "otherNumAffected": 0, "otherNumAtRisk": 4}], "seriousEvents": [{"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 340}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 201}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}]}, {"term": "Bile duct stone", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 340}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 201}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}]}, {"term": "Cholangitis acute", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 340}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 201}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}]}, {"term": "Cholecystitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 340}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 201}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 340}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 201}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 340}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 201}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 340}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 201}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 340}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 201}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}]}, {"term": "Intervertebral disc protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 340}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 201}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}]}, {"term": "Renal cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 340}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 201}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}]}, {"term": "Cerebral infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 340}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 201}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 340}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 201}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}]}, {"term": "Emphysema", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 340}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 201}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}]}, {"term": "Nasal septum deviation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 340}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 201}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}]}, {"term": "Pneumothorax", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 340}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 201}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}]}, {"term": "Pulmonary haemorrhage", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 340}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 201}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}]}], "otherEvents": [{"term": "Dysphagia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 340}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 201}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}]}, {"term": "Gastric ulcer", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 340}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 201}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 112}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}]}, {"term": "Gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 340}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 201}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}]}, {"term": "Gastritis erosive", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 340}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 201}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}]}, {"term": "Gingivitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 340}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 201}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}]}, {"term": "Oesophagitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 340}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 201}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}]}, {"term": "Peptic ulcer", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 340}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 201}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}]}, {"term": "Radicular cyst", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 340}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 201}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 37, "numAtRisk": 340}, {"groupId": "EG002", "numAffected": 15, "numAtRisk": 201}, {"groupId": "EG003", "numAffected": 15, "numAtRisk": 112}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 340}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 201}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 112}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 20, "numAtRisk": 340}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 201}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 112}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}]}, {"term": "Vestibular neuronitis", "organSystem": "Infections and infestations", "sourceVocabulary": "14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 340}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 201}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}]}, {"term": "Hyperuricaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 340}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 201}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 112}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 340}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 201}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 13, "numAtRisk": 340}, {"groupId": "EG002", "numAffected": 6, "numAtRisk": 201}, {"groupId": "EG003", "numAffected": 9, "numAtRisk": 112}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 340}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 201}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 112}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}]}, {"term": "Insomnia", "organSystem": "Psychiatric disorders", "sourceVocabulary": "14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 340}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 201}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 112}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 340}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 201}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 112}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}]}, {"term": "Rhinitis allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 340}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 201}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 112}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}, {"id": "D000075222", "term": "Essential Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M1470", "name": "Essential Hypertension", "asFound": "Essential Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "D000006852", "term": "Hydrochlorothiazide"}, {"id": "C000549068", "term": "Sacubitril and valsartan sodium hydrate drug combination"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000049993", "term": "Sodium Chloride Symporter Inhibitors"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M9910", "name": "Hydrochlorothiazide", "asFound": "Prescription", "relevance": "HIGH"}, {"id": "M350410", "name": "Sacubitril and valsartan sodium hydrate drug combination", "asFound": "Pea", "relevance": "HIGH"}, {"id": "M301", "name": "Valsartan", "relevance": "LOW"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M26152", "name": "Sodium Chloride Symporter Inhibitors", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}]}}, "hasResults": true}